Treatment rationale and design of the SPIRAL study: A phase II trial of osimertinib in elderly epidermal growth factor receptor T790M-positive nonsmall-cell lung cancer patients who progressed during prior EGFR-TKI treatment

BACKGROUND: Advances in epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) treatment led to research on the mechanism of the resistance have revealed that an occurrence of T790M gene mutation generated in exon 20 of the EGFR gene is associated with approximately 50% to 60% of obse...

Descripción completa

Detalles Bibliográficos
Autores principales: Uchino, Junji, Nakao, Akira, Tamiya, Nobuyo, Kaneko, Yoshiko, Yamada, Tadaaki, Yoshimura, Kenichi, Fujita, Masaki, Takayama, Koichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5999479/
https://www.ncbi.nlm.nih.gov/pubmed/29879078
http://dx.doi.org/10.1097/MD.0000000000011081

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5999479/
https://www.ncbi.nlm.nih.gov/pubmed/29879078
http://dx.doi.org/10.1097/MD.0000000000011081

Ejemplares similares